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CASE REPORT
A 77-year-old never-smoker woman, with a history of 
ischemic-hypertensive cardiopathy and diabetes, experiencing 
cough and dyspnea (performance status 2), underwent a total-
body computed tomography (CT) scan, which showed a large 
left pulmonary mass with ipsilateral parenchymal nodules and 
pleural effusion (Fig. 1A).
Pathological examination of a tumor cell block obtained 
from fine-needle aspiration of a 3-cm–sized nodule in the left 
lower lobe showed malignant epithelial cells with adenocarci-
noma structure (Fig. 2). Sequencing analysis of epidermal growth 
factor (EGFR) exons 18 to 21 upon genomic DNA extracted 
from the same paraffin-embedded material (3500-Dx Genetic 
Analyzer; Applied Biosystem Life Technologies, Carlsbad, CA) 
showed CTG-CAG point mutation (pL861Q) in exon 21.
Dual-color, break-apart fluorescent in situ hybridization 
(FISH) for ALK at 2p23 (ALK FISH DNA Probe; Split Signal, 
Dako, Glostrup, Denmark) and ROS1 at 6q22 (ZytoLight 
SPEC ROS1 Dual Color Break Apart Probe; ZytoVision, 
Bremerhaven, Germany) and dual-color FISH for MET/CEP7 
at 7q31 (ZytoLight SPEC MET/CEN 7 Dual Color Probe 
Zytovision) did not show any rearrangement, but an increased 
GCG was observed in 61%, 67%, and 72% cancer cells, with 
2.6, 2.6, and 2.9 mean signals per cell, respectively (Fig. 2).
The patient was started on gefitinib, 250 mg/day 
(September 18, 2012). Although an initial clinical benefit 
was observed (performance status 1), symptoms did rapidly 
worsen in the fifth to seventh weeks, and a CT scan (November 
7, 2012) showed progressive pleural disease and two brain 
metastasis (7 and 3 mm) (Fig. 1B: lung, Fig. 1C: brain).
Thus Gefitinib was stopped and given the patient’s per-
formance and comorbidities that did not allow to start chemo-
therapy, she was addressed to receive crizotinib 250 mg/twice 
a day on the basis of ALK, MET, and ROS1 increased GCN. 
After 4 weeks on crizotinib, a significant improvement of 
symptoms (cough and dyspnea) and performance status (0–1) 
was obtained. Treatment was well tolerated, except for a grade 
1 skin rash and increase of transaminases. The last CT scan 
(February 25, 2013; Fig. 1D) and clinical evaluation (March 5, 
2013) still confirm a stable disease after 4 months of crizotinib.
DISCUSSION
Only few cases of concurrent EGFR mutations (preva-
lently exon-19 deletions) and ALK rearrangement are currently 
on record.1 These coalterations seem even more anecdotal 
when accounting for EGFR rare point-mutations in exon 21, 
such as L861Q, and the presence of ALK GCG, whose clinical 
meaning is largely unknown. It is already known that patients 
with EGFR L861Q mutation may not have the same clinical 
benefit from gefitinib and erlotinib treatment as patients with 
classical EGFR  alterations, but may respond better to irre-
versible second-generation tyrosine kinase inhibitors (TKIs). 
Differently from the well-validated role of ALK translocation, 
no clinical reports describing a potential relationship between 
gene copy (GC) gain involving concurrently ALK, MET, and 
ROS1 genes and response to crizotinib have been reported to 
date. Although this cytogenetic event could have played a role 
in rapidly establishing resistance to EGFR-TKI, in this study 
we speculate that ALK, MET, and ROS1 GC gain could have 
been responsible for the success of the treatment with the rel-
evant inhibitor,2 despite the lack of the classical gene trans-
locations, and may be correlated with response to erlotinib. 
For example, we already know that MET amplification can 
be a mechanism of resistance to EGFR-TKIs and may predict 
response to crizotinib. Also, we would like to stress the need 
to accurately describe all cytogenetic alterations regarding 
ALK, ROS1, and MET genes when signing out the molecu-
lar pathology reports, to offer oncologists additional tools for 
deciding therapy. Although recent data have suggested that 
even patients with ALK GC gain could benefit from crizotinib 
treatment, this is the first evidence indicating that concurrent 
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GC gain of ALK, ROS1, and MET may become a predictive 
biomarker of response to crizotinib beyond translocation or 
amplification, although further evidence is required to vali-
date these preliminary data.
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FIGURE 1.  Radiological findings 
regarding different phases of the dis-
ease. A, Basal total-body computed 
tomography scan. B–C, Disease 
progression during treatment with 
gefitinib. D, Disease stability during 
treatment with crizotinib.
FIGURE 2.  Cytologic examination 
showed an adenocarcinoma (H&E), 
which presented with an increased 
GCN for ALK, MET, and ROS1 (immu-
nohistochemistry and fluorescent 
in situ hybridization analysis). H&E, 
hematoxylin and eosin.
